[期刊]
  • 《Pediatric nephrology: journal of the International Pediatric Nephrology Association》 2017年32卷1期

摘要 : Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment in steroid-dependent nephrotic syndrome (SDNS). However, some patients develop adverse reactions.

相关作者
相关关键词